Opinion|Videos|February 21, 2025
Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL
Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting emerging data that may refine their use in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), particularly in optimizing treatment duration and sequencing to improve patient outcomes.
Advertisement
Episodes in this series
- Were there any particularly exciting updates or data presented at ASH 2024 that could influence how BTK inhibitors are used in clinical practice for CLL and MCL?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
2
AI Model Flags Colorectal Cancer on Routine Noncontrast CT Scans
3
Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM
4
COPD Deaths Rival Heart Failure, Exceed Prostate and Breast Cancer
5